BioLife Solutions (BLFS) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Nov. 01, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-36362
Entity Registrant Name	BioLife Solutions, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 Monte Villa Parkway, Suite 310
Entity Address, City or Town	Bothell
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,031,322
Entity Central Index Key	0000834365
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,235	$ 19,442
Restricted cash	31	31
Available-for-sale securities, current portion	21,794	43,260
Accounts receivable, trade, net of allowance for credit losses of $1,244 and $739 as of September 30, 2023 and December 31, 2022, respectively	24,556	33,936
Inventories	43,354	34,904
Prepaid expenses and other current assets	7,854	6,879
Total current assets	116,824	138,452
Assets held for rent, net	7,209	9,064
Property and equipment, net	20,998	23,638
Operating lease right-of-use assets, net	12,651	15,292
Financing lease right-of-use assets, net	124	272
Long-term deposits and other assets	316	281
Available-for-sale securities, long-term	1,156	1,332
Equity investments	5,069	5,069
Intangible assets, net	22,064	32,088
Goodwill	224,741	224,741
Total assets	411,152	450,229
Current liabilities:
Accounts payable	11,980	15,367
Accrued expenses and other current liabilities	8,568	9,782
Sales taxes payable	5,469	4,151
Warranty liability	8,215	8,312
Lease liabilities, operating, current portion	2,906	2,860
Lease liabilities, financing, current portion	398	158
Debt, current portion	5,034	1,814
Contingent consideration, current portion	52	2,138
Total current liabilities	42,622	44,582
Contingent consideration, long-term	363	2,318
Lease liabilities, operating, long-term	13,677	14,962
Lease liabilities, financing, long-term	1,250	126
Debt, long-term	20,937	23,793
Deferred tax liabilities	286	250
Other long-term liabilities	0	10
Total liabilities	79,135	86,041
Commitments and contingencies (Note 13)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,831,351 and 42,832,231 shares issued and outstanding, respectively, as of September 30, 2023 and December 31, 2022	44	43
Additional paid-in capital	632,593	611,739
Accumulated other comprehensive loss, net of taxes	(660)	(679)
Accumulated deficit	(299,960)	(246,915)
Total shareholders’ equity	332,017	364,188
Total liabilities and shareholders’ equity	$ 411,152	$ 450,229

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Allowance for doubtful accounts	$ 1,244	$ 739
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	43,831,351	42,832,231
Common stock, shares outstanding (in shares)	43,831,351	42,832,231
Series A Preferred Stock
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total product, rental, and service revenue	$ 33,328	$ 40,747	$ 110,538	$ 117,500
Costs and operating expenses:
General and administrative	12,513	11,916	42,757	35,098
Sales and marketing	7,256	5,278	20,045	15,601
Research and development	5,402	3,425	14,397	10,634
Asset impairment charges	15,485	0	15,485	69,900
Intangible asset amortization	1,356	2,513	4,266	8,236
Change in fair value of contingent consideration	(1,580)	2,346	(1,778)	(3,348)
Total operating expenses	62,111	52,487	168,208	213,770
Operating loss	(28,783)	(11,740)	(57,670)	(96,270)
Other (expense) income:
Change in fair value of investments	0	697	0	697
Gain on settlement of Global Cooling escrow	0	0	5,115	0
Interest expense, net	(476)	(15)	(1,305)	(250)
Other income	242	142	1,027	270
Total other (expense) income, net	(234)	824	4,837	717
Loss before income tax (expense) benefit	(29,017)	(10,916)	(52,833)	(95,553)
Income tax (expense) benefit	(115)	599	(212)	4,937
Net loss	(29,132)	(10,317)	(53,045)	(90,616)
Net loss attributable to common shareholders:
Net loss attributable to common shareholders, basic	(29,132)	(10,317)	(53,045)	(90,616)
Net loss attributable to common shareholders, diluted	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Net loss per share attributable to common shareholders:
Net loss per share attributable to common shareholders, basic (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)
Net loss per share attributable to common shareholders, diluted (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)
Weighted average shares used to compute loss per share attributable to common shareholders:
Weighted average shares used to compute loss per share attributable to common shareholders, basic (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Weighted average shares used to compute loss per share attributable to common shareholders, diluted (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Product revenue
Total product, rental, and service revenue	$ 26,891	$ 33,668	$ 91,520	$ 98,227
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	16,665	21,876	57,022	63,377
Service revenue
Total product, rental, and service revenue	4,378	4,330	13,043	11,117
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	3,945	3,253	11,873	8,810
Rental revenue
Total product, rental, and service revenue	2,059	2,749	5,975	8,156
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	$ 1,069	$ 1,880	$ 4,141	$ 5,462

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax	(165)	(321)	(25)	(900)
Unrealized gain (loss) on available-for-sale securities, net of tax	4	(36)	44	(75)
Comprehensive loss	$ (29,293)	$ (10,674)	$ (53,026)	$ (91,591)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Series A Preferred Stock	Preferred Stock Series A Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance, preferred stock, shares outstanding (in shares) at Dec. 31, 2021			0
Beginning balance at Dec. 31, 2021	$ 478,047		$ 0	$ 42	$ 585,397	$ (282)	$ (107,110)
Beginning balance, common stock, shares outstanding (in shares) at Dec. 31, 2021				41,817,503
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Fees incurred for registration filings	(130)				(130)
Stock-based compensation	17,671				17,671
Stock option exercises (in shares)				158,075
Stock option exercises	307				307
Stock issued - on vested RSAs (in shares)				666,336
Stock issued – on vested RSAs	0			$ 1	(1)
Contingent consideration shares issued (in shares)				64,130
Contingent consideration shares issued	816				816
Foreign currency translation	(900)					(900)
Unrealized gain (loss) on available-for-sale securities	(75)					(75)
Net loss	(90,616)						(90,616)
Ending balance, preferred stock, shares outstanding (in shares) at Sep. 30, 2022			0
Ending balance at Sep. 30, 2022	405,120		$ 0	$ 43	604,060	(1,257)	(197,726)
Ending balance, common stock, shares outstanding (in shares) at Sep. 30, 2022				42,706,044
Beginning balance, preferred stock, shares outstanding (in shares) at Jun. 30, 2022			0
Beginning balance at Jun. 30, 2022	409,544		$ 0	$ 43	597,810	(900)	(187,409)
Beginning balance, common stock, shares outstanding (in shares) at Jun. 30, 2022				42,536,734
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Fees incurred for registration filings	(55)				(55)
Stock-based compensation	6,299				6,299
Stock option exercises (in shares)				3,571
Stock option exercises	6				6
Stock issued - on vested RSAs (in shares)				165,739
Foreign currency translation	(321)					(321)
Unrealized gain (loss) on available-for-sale securities	(36)					(36)
Net loss	(10,317)						(10,317)
Ending balance, preferred stock, shares outstanding (in shares) at Sep. 30, 2022			0
Ending balance at Sep. 30, 2022	405,120		$ 0	$ 43	604,060	(1,257)	(197,726)
Ending balance, common stock, shares outstanding (in shares) at Sep. 30, 2022				42,706,044
Beginning balance, preferred stock, shares outstanding (in shares) at Dec. 31, 2022		0	0
Beginning balance at Dec. 31, 2022	$ 364,188		$ 0	$ 43	611,739	(679)	(246,915)
Beginning balance, common stock, shares outstanding (in shares) at Dec. 31, 2022	42,832,231			42,832,231
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 23,337				23,337
Stock option exercises (in shares)				175,043
Stock option exercises	369				369
Stock issued - on vested RSAs (in shares)				923,128
Stock issued – on vested RSAs	1			$ 1
Contingent consideration shares issued (in shares)				116,973
Contingent consideration shares issued	2,263				2,263
Settlement of Global Cooling escrow (in shares)				(216,024)
Settlement of Global Cooling escrow	(5,115)				(5,115)
Foreign currency translation	(25)					(25)
Unrealized gain (loss) on available-for-sale securities	44					44
Net loss	(53,045)						(53,045)
Ending balance, preferred stock, shares outstanding (in shares) at Sep. 30, 2023		0	0
Ending balance at Sep. 30, 2023	$ 332,017		$ 0	$ 44	632,593	(660)	(299,960)
Ending balance, common stock, shares outstanding (in shares) at Sep. 30, 2023	43,831,351			43,831,351
Beginning balance, preferred stock, shares outstanding (in shares) at Jun. 30, 2023			0
Beginning balance at Jun. 30, 2023	$ 352,128		$ 0	$ 43	623,412	(499)	(270,828)
Beginning balance, common stock, shares outstanding (in shares) at Jun. 30, 2023				43,442,250
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	9,117				9,117
Stock option exercises (in shares)				31,000
Stock option exercises	64				64
Stock issued - on vested RSAs (in shares)				358,101
Stock issued – on vested RSAs	1			$ 1
Foreign currency translation	(165)					(165)
Unrealized gain (loss) on available-for-sale securities	4					4
Net loss	(29,132)						(29,132)
Ending balance, preferred stock, shares outstanding (in shares) at Sep. 30, 2023		0	0
Ending balance at Sep. 30, 2023	$ 332,017		$ 0	$ 44	$ 632,593	$ (660)	$ (299,960)
Ending balance, common stock, shares outstanding (in shares) at Sep. 30, 2023	43,831,351			43,831,351

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (53,045)	$ (90,616)
Adjustments to reconcile net loss to net cash used in operating activities
Impairment of intangible assets	5,758	69,900
Impairment of long-lived assets	9,727	0
Settlement of Global Cooling escrow	(5,115)	0
Depreciation	5,646	5,056
Amortization of intangible assets	4,266	8,236
Amortization of loan costs	13	0
Stock-based compensation	23,337	17,671
Non-cash lease expense	494	1,025
Deferred income tax expense (benefit)	36	(4,937)
Change in fair value of contingent consideration	(1,778)	(3,348)
Change in fair value of equity investments	0	(697)
Accretion of investments	(1,049)	0
Loss on disposal of property and equipment, net	227	54
Loss on disposal of assets held for rent, net	443	369
Other	0	302
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	9,437	(9,438)
Inventories	(8,450)	(5,403)
Prepaid expenses and other assets	(1,045)	(1,843)
Accounts payable	(3,380)	(3,615)
Accrued expenses and other current liabilities	(1,692)	444
Warranty liability	(97)	(1,031)
Sales taxes payable	1,330	1,526
Other	128	0
Net cash used in operating activities	(14,809)	(16,345)
Cash flows from investing activities
Purchases of available-for-sale securities	(22,688)	(35,767)
Proceeds from sale of available-for-sale securities	2,971	0
Maturities of available-for-sale securities	42,450	750
Purchases of assets held for rent	(3,453)	(2,269)
Purchases of property and equipment	(5,400)	(5,937)
Net cash provided by (used in) investing activities	13,880	(43,223)
Cash flows from financing activities
Payments on equipment loans	(383)	(370)
Proceeds from exercise of common stock options	370	307
Proceeds from term loans	0	20,000
Payments on term loans	300	1,750
Fees paid related to issuance of common stock	0	(130)
Proceeds from financed insurance premium	2,639
Payments on financed insurance premium	(1,653)	(814)
Other	77	(302)
Net cash provided by financing activities	750	16,941
Net decrease in cash, cash equivalents, and restricted cash	(179)	(42,627)
Cash, cash equivalents, and restricted cash – beginning of period	19,473	69,870
Effects of currency translation on cash, cash equivalents, and restricted cash	(28)	(176)
Cash, cash equivalents, and restricted cash – end of period	19,266	27,067
Non-cash investing and financing activities
Purchase of property and equipment not yet paid	4,064	1,661
Assets acquired under operating leases	(880)	243
Assets acquired under financing leases	1,682	0
Unrealized gains and losses on currency translation	(11)	0
Unrealized gains and losses on available-for-sale securities	(44)	75
Cashless issuance of SciSafe earnout shares	2,263	817
Supplemental Cash Flow Information [Abstract]
Cash interest paid	1,394	230
Returned shares from settlement of Global Cooling escrow	$ (5,115)	$ 0

Organization and significant ac

Organization and significant accounting policies	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and significant accounting policies	Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers, and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ to negative 86℃. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our biological and pharmaceutical materials storage services provide facilities that allow for real-time tracking of biologic materials and vaccines that can be stored at a wide range of temperatures. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three and nine months ended September 30, 2023 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2023 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023 (the “Annual Report”). The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, Global Cooling, Inc. doing business as Stirling Ultracold (“Global Cooling” or “GCI”), and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Comprehensive Loss, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Significant accounting policies There have been no significant changes to the accounting policies during the three and nine months ended September 30, 2023, as compared to the significant accounting policies described in our Annual Report. Liquidity and capital resources On September 30, 2023 and December 31, 2022, we had $42.2 million and $64.1 million in cash, cash equivalents, and available-for-sale securities, respectively. We have the ability to borrow up to $10 million under our Loan Agreement (as defined in Note 14 below). For additional information, see Note 14. Additionally, on October 19, 2023, we entered into a Securities Purchase Agreement with Casdin Partners Master Fund, L.P. ("Casdin") whereby the Company sold, and Casdin purchased, 927,165 shares of common stock of the Company at a share price of $11.19 per share for an aggregate purchase price of $10,374,976, infusing additional capital into the Company. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q. Risks and uncertainties Supply chain considerations Our domestic and international supply chain operations were affected by the global pandemic of the coronavirus (“COVID-19”) and the resulting volatility and uncertainty it caused in the U.S. and international markets. The onset of the COVID-19 pandemic caused supply chains globally to become constrained, and these constraints historically impacted our business through both increased difficulty in obtaining semiconductor chips and increased pricing on available parts. However, as of the nine months ended September 30, 2023, both availability and pricing of semiconductor chips have improved and no longer pose constraints on our supply chain. We currently have sufficient supply for electrical component parts within our operations and do not foresee constraints to return over our supply chain. Concentrations of credit risk and business risk Significant customers are those that represent more than 10% of the Company’s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue September 30, December 31, Three Months Ended Nine Months Ended 2023 2022 2023 2022 2023 2022 Customer A * 15 % * * * * Customer B 11 % * 19 % 17 % 16 % 19 % Customer C * 11 % * * * * * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s products representing more than 10% of the Company’s total revenues: Three Months Ended Nine Months Ended Product revenue concentration 2023 2022 2023 2022 CryoStor 33 % 38 % 39 % 35 % 780XLE Freezer 23 % 21 % 19 % 22 % The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended Revenue by customers ’ geographic locations (1) 2023 2022 2023 2022 North America (2) 81 % 81 % 81 % 81 % Europe, Middle East, Africa (EMEA) 15 % 16 % 16 % 16 % Other 4 % 3 % 3 % 3 % Total revenue 100 % 100 % 100 % 100 % (1) During the nine months ended September 30, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented. (2) The line item presented above previously bifurcated sales between the United States and Canada. Due to the updated methodology for determining the country of origin for sales, it was noted that Canada no longer was a material location to separately disclose. Both have been combined in the line item presented above to more accurately reflect origin of sales for material regions. In the three and nine months ended September 30, 2023, one supplier accounted for 14% and 12% of purchases, respectively. In the three and nine months ended September 30, 2022, no suppliers accounted for more than 10% of purchases. As of September 30, 2023, one supplier accounted for 19% of our accounts payable. As of December 31, 2022, one supplier accounted for 23% of our accounts payable. Recent accounting pronouncements As of January 1, 2023, we adopted the ASC 2016-13, Measurement of Credit Losses on Financial Instruments, which later was codified as ASC 326 (CECL). In addition to the adoption of ASC 326, the Company adopted the accompanying ASU No. 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Both standards mark a significant change requiring the immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets. ASU 2022-02 specifically eliminates the accounting guidance for troubled debt restructurings and requires disclosure of current-period gross write-offs by year of loan origination. Additionally, ASU 2022-02 updates the accounting for credit losses under ASC 326 and adds enhanced disclosures with respect to loan refinancings and restructurings in the form of principal forgiveness, interest rate concessions, other-than-insignificant payment delays, or term extensions when the borrower is experiencing financial difficulties. ASC 326 is intended to improve financial reporting by corporations by requiring earlier recognition of credit losses on loans from corporations, held-to-maturity (HTM) securities, and certain other financial assets. ASC 326 also amended the impairment guidance for available-for-sale (AFS) debt securities in that it eliminated the Other Than Temporary Impairment (OTTI) impairment model. Under Subtopic ASC 326-30, Financial Instruments—Credit Losses—Available-for-Sale Debt Securities, changes in expected cash flows due to credit on AFS debt securities will be recorded through an allowance, rather than permanent write-downs for negative changes and prospective yield adjustments for positive changes, as required by the current OTTI model. ASC 326 replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. For the period ended September 30, 2023, the adoption of ASC 326 did not result in a material effect on the Company’s Unaudited Condensed Consolidated financial statements.

Correction of immaterial errors

Correction of immaterial errors	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Correction of immaterial errors	Correction of immaterial errors As reported in our Annual Report, we determined that an error existed in our previously issued consolidated financial statements. Specifically, we identified we had established nexus in several jurisdictions beginning in the year ended December 31, 2019 in which we were not collecting and remitting sales taxes appropriately. The error was evaluated and recorded as of each period impacted by the error under the SEC guidance on evaluating the materiality of prior period misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not material to any previously issued consolidated financial statements and accompanying Unaudited Condensed Consolidated financial statements. Although the error was not material to any period, we corrected the accompanying historical Unaudited Condensed Consolidated financial statements for each period impacted. The corrections to the quarter ended September 30, 2022 are presented below to reflect the sales tax liability and associated expenses owed within the period for comparative purposes. The effect of the adjustments to our Unaudited Condensed Consolidated Balance Sheet as of September 30, 2022 was as follows: September 30, 2022 (In thousands) As reported Adjustment As corrected Prepaid expenses and other current assets $ 8,041 $ 341 $ 8,382 Total current assets 135,874 341 136,215 Total assets 487,679 341 488,020 Accrued expenses and other current liabilities 7,778 (340) 7,438 Sales taxes payable - 3,810 3,810 Total current liabilities 36,948 3,470 40,418 Total liabilities 79,430 3,470 82,900 Accumulated deficit (194,597) (3,129) (197,726) Total shareholders’ equity 408,249 (3,129) 405,120 Total liabilities and shareholders’ equity 487,679 341 488,020 The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Operations for the quarter ended September 30, 2022 was as follows: Three Months Ended Nine Months Ended (In thousands, except per share and share data) As reported Adjustment As corrected As reported Adjustment As corrected General and administrative $ 11,581 $ 335 $ 11,916 $ 34,128 $ 970 $ 35,098 Total operating expenses 52,152 335 52,487 212,800 970 213,770 Operating loss (11,405) (335) (11,740) (95,300) (970) (96,270) Interest income (expense) 10 (25) (15) (181) (69) (250) Total other income, net 849 (25) 824 786 (69) 717 Loss before income tax benefit (10,556) (360) (10,916) (94,514) (1,039) (95,553) Net loss (9,957) (360) (10,317) (89,577) (1,039) (90,616) Net loss per basic and diluted share (0.23) (0.01) (0.24) (2.11) (0.03) (2.14) The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Cash Flows for the quarter ended September 30, 2022 was as follows: Nine Months Ended (In thousands) As reported Adjustment As corrected Net loss $ (89,577) $ (1,039) $ (90,616) Prepaid expenses and other current assets (1,356) (487) (1,843) Sales taxes payable - 1,526 1,526

Impairment of property and equi

Impairment of property and equipment and definite-lived intangible assets	9 Months Ended
	Sep. 30, 2023
Asset Impairment Charges [Abstract]
Impairment of property and equipment and definite-lived intangible assets	Impairment of property and equipment and definite-lived intangible assets Subsequent to the second quarter of 2023, the Company began to actively seek divestment of its GCI and CBS freezer product lines (the "Freezer Business"). The announcement, coupled with broader economic uncertainty leading to reductions in spending across the biopharma industry and the Company's customer base constituted interim triggering events that required further analysis with respect to potential impairment to goodwill, indefinite-lived intangibles, and its long-lived asset groups. The Company performed an interim quantitative impairment test as of the September 30, 2023 balance sheet date. To assess any potential impairment of goodwill, the Company compared the carrying value of its single reporting unit against its market capitalization, noting that the market capitalization exceeded the carrying value. As such, goodwill was not impaired as of September 30, 2023. As a part of the interim quantitative impairment analysis performed, the Company determined that decreases in the market price of the GCI long-lived asset group and historical operating cash flow losses for both GCI and CBS were indicative of potential impairment. The recoverability tests performed over the asset groups of the Freezer Business resulted in a $9.7 million non-cash impairment charge over property and equipment and a $5.8 million non-cash impairment charge over definite-lived intangible assets reflected in the Company's Unaudited Condensed Consolidated Statements of Operations, which represents the entirety of the asset groups' carrying value. In order to determine the fair value of the property and equipment, acquired technology, customer relationships, and tradename definite-lived intangible assets, the Company utilized the market approach and discounted cash flow analyses to determine if the recoverability of the Freezer Business asset groups were above its carrying value. The key assumptions associated with determining the estimated fair value include (i) the amount and timing of projected future cash flows (including revenue and expenses), (ii) the discount rate selected to measure the risks inherent in the future cash flows, (iii) the assessment of the asset’s life cycle, and (iv) the competitive trends impacting the asset. As a result of the analysis, we recognized non-cash impairment charges of $9.7 million, $3.1 million, $0.2 million, and $2.5 million during the period ended September 30, 2023 for the property and equipment, acquired technology, customer relationships, and tradename definite-lived intangible assets, respectively, in the line item titled, " Asset impairment charges " in the Company's Unaudited Condensed Consolidated Statements of Operations, which represents the difference between the estimated fair value of the Company’s definite-lived intangible assets and their carrying values. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions, estimates and market factors. Estimating the fair value of the Company’s reporting unit and definite-lived intangible assets requires us to make assumptions and estimates regarding our future plans, as well as industry, economic, and regulatory conditions. These assumptions and estimates include projected future revenue growth rates, EBITDA margins, terminal growth rates, discount rates, royalty rates and other market factors. If current expectations of future growth rates, margins and cash flows are not met, or if market factors outside of our control change significantly, then our reporting unit, indefinite-lived intangible assets, and definite-lived intangible assets might become impaired in the future, negatively impacting our operating results and financial position. As the carrying amounts of the Company’s definite-lived intangible assets were impaired as of September 30, 2023 and written down to fair value, those amounts are more susceptible to an impairment risk if there are unfavorable changes in assumptions and estimates.

Fair value measurement

Fair value measurement	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement In accordance with FASB ASC Topic 820, the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. The Company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The fair value of the SciSafe Contingent Consideration Liability was valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not affect the fair value of the contingent consideration if they increase (decrease) beyond certain amounts. At the acquisition date, the contingent consideration was determined to have a fair value of $3.7 million. Subsequent to the acquisition date, the SciSafe Contingent Consideration Liability was re-measured to fair value with changes recorded in the Change in Fair Value of Contingent Consideration in the Unaudited Condensed Consolidated Statements of Operations. During the most recent re-measurement of the SciSafe Contingent Consideration Liability as of September 30, 2023, the Company used a discount rate of 14.5%, a risk-free rate of approximately 4.9%, asset volatility of 71%, and revenue volatility of 36%. The SciSafe Contingent Consideration Liability is included in the Unaudited Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 in the amounts of $0.3 million and $4.3 million, respectively. The changes in fair value of contingent consideration associated with this liability are included within the Change in Fair Value of Contingent Consideration in the Unaudited Condensed Consolidated Statements of Operations. These changes in fair value of contingent consideration associated with this liability are included within the Change in Fair Value of Contingent Consideration in the Unaudited Condensed Consolidated Statements of Operations. These changes were $1.6 million and $1.8 million of benefit for the three and nine months ended September 30, 2023, respectively, and $2.3 million of expense and $3.3 million of benefit for the three and nine months ended September 30, 2022, respectively. As of the year ended December 31, 2022, the second hurdle associated with this liability was satisfied and 116,973 shares were issued as payment during the second quarter of 2023. There were no remeasurements to fair value during the three and nine months ended September 30, 2023 of financial assets and liabilities that are not measured at fair value on a recurring basis. The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, based on the three-tier fair value hierarchy: (In thousands) As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 12,392 $ - $ - $ 12,392 Available-for-sale securities: U.S. government securities 5,028 - - 5,028 Corporate debt securities - 15,898 - 15,898 Other debt securities - 2,024 - 2,024 Total $ 17,420 $ 17,922 $ - $ 35,342 Liabilities: Contingent consideration - business combinations - - 415 415 Debt - 25,971 - 25,971 Total $ - $ 25,971 $ 415 $ 26,386 As of December 31, 2022 Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total $ 26,467 $ 29,541 $ - $ 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063 There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Nine Months Ended September 30, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 4,456 $ 10,027 Change in fair value recognized in net loss (1,778) (3,348) Payment of contingent consideration earned (2,263) (817) Ending balance $ 415 $ 5,862

Investments

Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: September 30, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,030 $ - $ 2 $ 5,028 Corporate debt securities 15,901 1 4 15,898 Other debt securities 868 - - 868 Total short-term 21,799 1 6 21,794 Available-for-sale securities, long-term Other debt securities 1,158 2 4 1,156 Total marketable securities $ 22,957 $ 3 $ 10 $ 22,950 December 31, 2022 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 15,087 $ 1 $ 37 $ 15,051 Corporate debt securities 26,057 6 16 26,047 Other debt securities 2,169 - 7 2,162 Total short-term 43,313 7 60 43,260 Available-for-sale securities, long-term Other debt securities 1,329 3 - 1,332 Total marketable securities $ 44,642 $ 10 $ 60 $ 44,592 September 30, 2023 (In thousands) Amortized Estimated Due in one year or less $ 21,799 $ 21,794 Due after one year through five years 1,158 1,156 Total $ 22,957 $ 22,950 Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series A-1 and A-2 Preferred Stock in iVexSol, Inc. carried at $4.1 million for the periods ending September 30, 2023 and December 31, 2022, and Series E Preferred Stock in PanTHERA CryoSolutions, Inc. carried at $995,000 as of September 30, 2023 and December 31, 2022.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Raw materials $ 24,452 $ 20,950 Work in progress 5,973 5,680 Finished goods 12,929 8,274 Total inventories $ 43,354 $ 34,904

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one one one Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Weighted average discount rate - operating leases 4.3 % 4.2 % Weighted average discount rate - finance leases 8.3 % 6.1 % Weighted average remaining lease term in years - operating leases 6.5 7.2 Weighted average remaining lease term in years - finance leases 4.3 2.0 The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Operating lease costs $ 883 $ 909 $ 2,679 $ 2,745 Short-term lease costs 560 534 1,410 1,627 Total operating lease costs 1,443 1,443 4,089 4,372 Variable lease costs 299 250 903 809 Total lease costs $ 1,742 $ 1,693 $ 4,992 $ 5,181 Maturities of our lease liabilities as of September 30, 2023 are as follows: (In thousands) Operating Financing 2023 (3 months remaining) $ 909 $ 134 2024 3,383 487 2025 2,942 424 2026 2,532 389 2027 2,280 387 Thereafter 6,938 134 Total lease payments 18,984 1,955 Less: interest (2,401) (307) Total present value of lease liabilities $ 16,583 $ 1,648
Leases	Leases The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one one one Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Weighted average discount rate - operating leases 4.3 % 4.2 % Weighted average discount rate - finance leases 8.3 % 6.1 % Weighted average remaining lease term in years - operating leases 6.5 7.2 Weighted average remaining lease term in years - finance leases 4.3 2.0 The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Operating lease costs $ 883 $ 909 $ 2,679 $ 2,745 Short-term lease costs 560 534 1,410 1,627 Total operating lease costs 1,443 1,443 4,089 4,372 Variable lease costs 299 250 903 809 Total lease costs $ 1,742 $ 1,693 $ 4,992 $ 5,181 Maturities of our lease liabilities as of September 30, 2023 are as follows: (In thousands) Operating Financing 2023 (3 months remaining) $ 909 $ 134 2024 3,383 487 2025 2,942 424 2026 2,532 389 2027 2,280 387 Thereafter 6,938 134 Total lease payments 18,984 1,955 Less: interest (2,401) (307) Total present value of lease liabilities $ 16,583 $ 1,648

Assets held for rent

Assets held for rent	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Assets held for rent	Assets held for rent Assets held for rent consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Shippers placed in service $ 9,848 $ 7,671 Fixed assets held for rent 1,562 4,686 Accumulated depreciation (5,778) (4,952) Subtotal 5,632 7,405 Shippers and related components in production 1,577 1,659 Total $ 7,209 $ 9,064 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.9 million and $2.8 million in depreciation expense related to assets held for rent during the three and nine months ended September 30, 2023, respectively, and $0.9 million and $2.7 million during the three and nine months ended September 30, 2022, respectively.

Property and equipment

Property and equipment	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment Property and equipment consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Property and equipment (1) Leasehold improvements $ 5,948 $ 5,249 Furniture and computer equipment 1,046 1,908 Manufacturing and other equipment 19,862 20,557 Construction in-progress 3,500 5,095 Subtotal 30,356 32,809 Less: Accumulated depreciation (9,358) (9,171) Property and equipment, net $ 20,998 $ 23,638 (1) The entirety of the carrying values and accumulated depreciation of the Freezer Business property and equipment assets were impaired during the three months ended September 30, 2023. Refer to Note 3: Impairment of property and equipment and definite-lived intangible assets for more information on the assessed non-cash impairment charges. Depreciation expense for property and equipment was $1.0 million and $2.9 million for the three and nine months ended September 30, 2023, respectively, and $0.9 million and $2.4 million during the three and nine months ended September 30, 2022, respectively.

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350. Intangible assets Intangible assets, net consisted of the following as of September 30, 2023 and December 31, 2022: (In thousands, except weighted average useful life) September 30, 2023 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships (1) $ 9,936 $ (4,081) $ 5,855 10.9 Tradenames (1) 8,134 (1,921) 6,213 11.5 Technology - acquired (1) 18,372 (8,541) 9,831 4.3 Non-compete agreements 750 (585) 165 1.0 Total intangible assets $ 37,192 $ (15,128) $ 22,064 7.6 (1) The entirety of the gross carrying values and accumulated amortization of the specified intangible assets above associated with the Freezer Business were impaired during the three months ended September 30, 2023. Refer to Note 3: Impairment of property and equipment and definite-lived intangible assets for more information on the assessed non-cash impairment charges. (In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value (1) Accumulated Amortization (1) Net Carrying Value Weighted Average Useful Life (in years) (1) Customer relationships $ 10,496 $ (3,328) $ 7,168 8.8 Tradenames 11,328 (1,794) 9,534 11.8 Technology - acquired 23,802 (8,705) 15,097 5.3 Non-compete agreements 750 (461) 289 1.8 Total intangible assets $ 46,376 $ (14,288) $ 32,088 8.0 (1) Both the Gross Carrying Value and Accumulated Amortization balances as of December 31, 2022 contain immaterial adjustments to reflect impairments taken during the year ended December 31, 2022 on each of the intangible asset classes presented here. Each intangible asset class was adjusted as follows: Customer relationships: $0.8 million, Tradenames: $2.4 million, Technology - acquired: $4.1 million, and Non-compete agreements: $0.4 million. The Weighted Average Useful Life was additionally adjusted to reflect the updated balances subsequent to the impairment charges. Amortization expense for definite-lived intangible assets was $1.4 million and $4.3 million for the three and nine months ended September 30, 2023, respectively and $2.5 million and $8.2 million for the three and nine months ended September 30, 2022, respectively. As of September 30, 2023, the Company expects to record the following amortization expense for definite-lived intangible assets: (In thousands) Amortization For the Years Ending December 31, 2023 (3 months remaining) $ 915 2024 3,602 2025 3,468 2026 3,358 2027 2,605 Thereafter 8,116 Total $ 22,064

Accrued expenses and other curr

Accrued expenses and other current liabilities	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Accrued compensation $ 3,309 $ 5,080 Accrued expenses 3,704 3,128 Deferred revenue, current 660 548 Accrued taxes 895 975 Other - 51 Total accrued expenses and other current liabilities $ 8,568 $ 9,782

Warranty reserve liability

Warranty reserve liability	9 Months Ended
	Sep. 30, 2023
Guarantees and Product Warranties [Abstract]
Warranty reserve liability	Warranty reserve liability The Company reserves estimated exposures on known claims, as well as anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Nine Months Ended (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 8,312 $ 9,398 Provision for warranties (1) 2,861 2,353 Settlements of warranty claims (1) (2,958) (3,384) Ending balance $ 8,215 $ 8,367

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason. Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none of which are currently material to the Company’s business. The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company. Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of September 30, 2023 and December 31, 2022. Purchase obligations Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of September 30, 2023, our total short-term obligations were $14.3 million. Non-income related taxes Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2022, the Company determined that a sales tax liability related to the periods of 2019 through 2022 was probable and determined an estimated liability. The estimated liability was approximately $5.2 million and $3.7 million as of September 30, 2023 and December 31, 2022, respectively. Outside of the analysis performed to determine the sales tax liability related to the periods of 2019 through 2022, we assessed approximately $0.1 million and $0.3 million of sales tax obligations generated during the normal course of business as of September 30, 2023 and December 31, 2022, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period. Settlement of Global Cooling escrow On May 3, 2021, the Company acquired GCI pursuant to an Agreement and Plan of Merger, dated as of March 19, 2021 (the “GCI Merger Agreement”). Pursuant to the GCI Merger Agreement, the aggregate consideration paid to former stockholders of GCI (collectively, the “GCI Stockholders”) was 6,646,870 newly issued shares of common stock (the “GCI Merger Consideration”) were provided with the requirement that the GCI Merger Consideration otherwise payable to GCI Stockholders were subject to reduction for indemnification obligations. Approximately 9% of the GCI Merger Consideration (the "GCI Escrow Shares") otherwise issuable to the GCI Stockholders were deposited into a segregated escrow account (the “GCI Escrow Account”) in accordance with an escrow agreement entered into in connection with the closing of the transactions contemplated by the GCI Merger Agreement (the “GCI Escrow Agreement”). Of the GCI Escrow Shares, an amount equal to 5% of the GCI Merger Consideration were considered general escrow shares (the “General Escrow Shares”). The General Escrow Shares were eligible to be held in escrow for a period of up to 18 months after the closing of the GCI acquisition as the sole and exclusive source of payment for any indemnification claims made by the Company. On September 28, 2022, BioLife asserted an indemnification claim pursuant to the GCI Merger Agreement. On June 5, 2023, the Company entered into a Settlement Agreement with the representatives of the GCI Stockholders, pursuant to which the parties agreed to release 65% of the General Escrow Shares, totaling 216,024 shares, to the Company from the GCI Escrow Account. These shares were returned to the Company and subsequently cancelled. As a result of the settlement, the Company recorded a $5.1 million gain recognizing the return of the shares during the second quarter of 2023.

Long-term debt

Long-term debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-term debt	Long-term debt 2022 term loan 2 Upon acquisition of Global Cooling in May 2021, the Company assumed three term notes. In October 2021, the Company entered into amended and restated term notes for all three term notes. Pursuant to the loan agreements, one lender provided two term notes in the amounts of $1.4 million and $1.4 million. A separate lender provided one term note in the amount of $1.8 million. All three term notes bear interest at a fixed rate of 4%, were interest-only with one balloon principal payment at maturity, and could be pre-paid without penalty at any time. As of September 20, 2022, the Company fully extinguished one of the three term notes. All financial covenants included in the original agreements previously in effect were removed by the amended loan agreements. 2022 term loan 3 On September 20, 2022, the Company and certain of its subsidiaries entered into a term loan agreement, which provided for up to $50.0 million in aggregate principal to be drawn. The term loan matures on June 1, 2026. The agreement provided for borrowings of up to $30.0 million upon closing and options to borrow up to $10.0 million between closing and June 30, 2023, up to $10.0 million upon the achievement of certain revenue milestones, and an additional $10.0 million at the discretion of the lender. The Company borrowed $20.0 million upon closing. As of September 30, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the term loan agreement. The Company has until December 31, 2023 to draw an additional $10.0 million, subject to approval from the lender. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the term loan agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the term loan in full, or termination of the loan agreement at $1.2 million. The term loan agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of September 30, 2023, the Company is in compliance with the covenants set forth in the 2022 term loan 3 agreement. In the event that borrowings under 2022 term loan 3 exceed $20.0 million, the Company will become subject to certain financial covenants. Long-term debt consisted of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) Maturity Date Interest Rate 2023 2022 2022 term loan 2 Various 4.0 % 2,596 2,896 2022 term loan 3 Jun-26 7.0 % 20,000 20,000 Insurance premium financing Apr-24 8.0 % 2,061 1,074 Freezer equipment loan Dec-25 5.7 % 355 466 Manufacturing equipment loans Oct-25 5.7 % 195 266 Freezer installation loan Various 6.3 % 876 1,078 Other loans Various Various 3 6 Total debt, excluding unamortized debt issuance costs 26,086 25,786 Less: unamortized debt issuance costs (115) (179) Total debt 25,971 25,607 Less: current portion (5,034) (1,814) Total long-term debt $ 20,937 $ 23,793 2022 term loan 3 is secured by substantially all assets of BioLife, SAVSU, CBS, SciSafe, Global Cooling and Sexton, other than intellectual property. 2022 term loan 2 is secured by substantially all assets of Global Cooling and is effectively subordinated to the security interest established by the lenders of 2022 term loan 3. Equipment loans are secured by the financed equipment. As of September 30, 2023, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2023 (3 months remaining) $ 816 2024 6,830 2025 10,511 2026 5,218 2027 2,596 Thereafter - Total debt $ 25,971

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	RevenueTo determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of September 30, 2023 and December 31, 2022, our deferred revenue balance totaled $0.7 million and $0.6 million, respectively. During the three and nine months ended September 30, 2023, the Company recognized approximately $0.1 million and $0.4 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year. During the three and nine months ended September 30, 2022, the Company recognized approximately $26 thousand and $0.5 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year. The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three and nine months ended September 30, 2023. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its biostorage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under month-to-month rental arrangements. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term. The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one customer. This is primarily driven by the customer’s desire to ensure that sufficient storage capacity is available in a specific geographic location for a set period of time. These agreements may include extension and termination clauses. These Service Contracts do not allow for customers to purchase the underlying assets. The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Applying the practical expedient from ASC Topic 842, consistent with the previous guidance, the Company will continue to recognize operating right-of-use asset embedded lessor arrangements on its Unaudited Condensed Consolidated Balance Sheets in operating right-of-use assets. None of the Embedded Leases identified by the Company qualify as a sales-type or direct finance lease. None of the operating leases for which the Company is the lessor include options for the lessee to purchase the underlying asset at the end of the lease term or residual value guarantees, nor are any such operating leases with related parties. Embedded Leases may contain both lease and non-lease components. We have elected to utilize the practical expedient from ASC Topic 842 to account for lease and non-lease components together as a single combined lease component as the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease. Non-lease components of the Company’s rental arrangements include reimbursements of lessor costs. Total bioproduction tools and services revenue for the three and nine months ended September 30, 2023 and 2022 were composed of the following: Three Months Ended Nine Months Ended (In thousands, except percentages) 2023 2022 2023 2022 Product revenue Freezer and thaw $ 13,188 $ 15,326 $ 39,417 $ 49,331 Cell processing 13,338 18,082 51,004 48,336 Biostorage services 365 260 1,099 560 Service revenue Biostorage services 4,186 4,312 12,166 11,099 Freezer and thaw 192 18 877 18 Rental revenue Biostorage services 2,059 2,749 5,975 8,156 Total revenue $ 33,328 $ 40,747 $ 110,538 $ 117,500 The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers. The estimated revenue in the following table does not include contracts with the original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2023. The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: (In thousands) 2023 (3 months remaining) 2024 Total Rental revenue $ 900 $ 900 $ 1,800 Service revenue $ 313 $ 10 $ 323

Stock-based compensation

Stock-based compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the September 30, 2023, and the status of service vesting-based stock options outstanding as of September 30, 2023: Nine Months Ended Options Wtd. Avg. Exercise Price Outstanding as of beginning of year 456,293 $ 2.17 Exercised (175,043) 2.11 Outstanding as of September 30, 2023 281,250 $ 2.19 Stock options exercisable as of September 30, 2023 281,250 $ 2.19 As of September 30, 2023, there was $3.3 million of aggregate intrinsic value of outstanding and exercisable service vesting-based stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on September 30, 2023. This amount will change based on the fair market value of the Company’s stock. Intrinsic value of service vesting-based awards exercised was $0.5 million and $3.3 million during the three and nine months ended September 30, 2023, respectively. There were no service-based vesting options granted during the three and nine months ended September 30, 2023. The weighted average remaining contractual life of service vesting-based options outstanding and exercisable as of September 30, 2023 is 2.3 years. There were no unrecognized compensation costs for service vesting-based stock options as of September 30, 2023. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the three and nine months ended September 30, 2023, and the status of unvested service vesting-based restricted stock outstanding as of September 30, 2023: Nine Months Ended Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,879,215 $ 28.94 Granted 584,976 17.57 Vested (892,512) 25.95 Forfeited (151,984) 28.25 Non-vested as of September 30, 2023 1,419,695 $ 26.21 The aggregate fair value of the service vesting-based awards granted was $1.0 million and $16.8 million during the three and nine months ended September 30, 2023, respectively. The aggregate fair value of the service vesting-based awards that vested was $5.0 million and $16.9 million during the three and nine months ended September 30, 2023, respectively. We recognized stock compensation expense related to service vesting-based awards of $9.1 million and $23.3 million during the three and nine months ended September 30, 2023, respectively. As of September 30, 2023, there was $33.0 million in unrecognized compensation costs related to service vesting-based awards. We expect to recognize those costs over 2.2 years. Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the three and nine months ended September 30, 2023 and the status of market-based restricted stock outstanding as of September 30, 2023: Nine Months Ended Shares Wtd. Avg. Grant Outstanding as of beginning of year 271,044 $ 30.64 Granted 268,738 19.67 Vested (30,616) 51.65 Non-vested as of September 30, 2023 509,166 $ 26.00 On February 8, 2021, the Company granted 30,616 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. On March 31, 2023, the Company’s Compensation Committee determined the TSR attainment was 100% of the targeted shares and 30,616 shares were granted and immediately vested to the executives of the Company based on our total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined at the grant date using a Monte Carlo simulation with the following assumptions: a historical volatility of 68%, 0% dividend yield and a risk-free interest rate of 0.1%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $1.3 million was being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2022. On February 24, 2022, the Company granted 240,428 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 63%, 0% dividend yield and a risk-free interest rate of 1.5%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.7 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2023. On January 8, 2023, the Company granted 268,738 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 78%, 0% dividend yield and a risk-free interest rate of 4.4%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024. We recognized stock compensation expense of $1.6 million and $4.9 million related to market-based restricted stock awards for the three and nine months ended September 30, 2023, respectively, and $1.2 million and $3.1 million during the three and nine months ended September 30, 2022. As of September 30, 2023, there was $4.9 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. We expect to recognize those costs over 1.1 years. There were no market-based awards granted or vested during the three months ended September 30, 2023 and September 30, 2022. The aggregate fair value of the market-based awards granted was $6.5 million during the nine months ended September 30, 2023, and $6.7 million during the nine months ended September 30, 2022. The aggregate fair value of the market-based awards that vested was $0.7 million during the nine months ended September 30, 2023, and $5.0 million during the nine months ended September 30, 2022. Total stock compensation expense Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4 year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three and nine months ended September 30, 2023 and 2022, as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Cost of revenue $ 1,409 $ 809 $ 4,252 $ 2,619 General and administrative costs 3,696 3,959 10,544 10,687 Sales and marketing costs 2,225 829 4,563 2,272 Research and development costs 1,787 702 3,978 2,093 Total $ 9,117 $ 6,299 $ 23,337 $ 17,671

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax expense of $0.2 million for the nine months ended September 30, 2023 resulted in an effective income tax rate of negative 0.4%. Included in the $0.2 million was a discrete tax benefit of $1.2 million related to stock compensation shortfall tax expenses, which were offset by a change in the valuation allowance. The Company’s US projected effective income tax rate without discrete items was negative 0.4%, which is lower than the US federal statutory rate of 21% primarily due to the increase in the valuation allowance on US deferred tax assets and non-deductible executive compensation offset by a non-taxable gain, state tax benefits, and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not that deferred tax assets are realizable. After reviewing the evidence available, the Company’s management believes there is uncertainty regarding the future realizability of the U.S. net operating loss carryforward and is projecting a full valuation allowance of $48.2 million by year end. If operating results improve and projections indicate future utilization of the tax attributes, all or a portion of the valuation allowance would be released, resulting in a corresponding non-cash income tax benefit.

Net loss per common share

Net loss per common share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net loss per common share	Net loss per common share The Company considers its unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two-class method. Basic earnings per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. The following table presents computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended (In thousands, except share and earnings per share data) 2023 2022 2023 2022 Basic earnings (loss) per common share Numerator: Net loss $ (29,132) $ (10,317) $ (53,045) $ (90,616) Net loss allocated to common shareholders (29,132) (10,317) (53,045) (90,616) Denominator: Weighted-average common shares issued and outstanding 43,570,438 42,647,967 43,348,412 42,376,392 Basic and diluted loss per common share $ (0.67) $ (0.24) $ (1.22) $ (2.14) The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Stock options and restricted stock awards 2,636,283 2,022,405 3,007,126 2,678,601 Total 2,636,283 2,022,405 3,007,126 2,678,601

Employee benefit plan

Employee benefit plan	9 Months Ended
	Sep. 30, 2023
Retirement Benefits [Abstract]
Employee benefit plan	Employee benefit planThe Company sponsors 401(k) defined contribution plans for its employees. These plans provide for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to these plans, as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.3 million and $0.9 million in contributions to the plan for the three and nine months ended September 30, 2023, respectively, and $0.3 million and $0.8 million for the three and nine months ended September 30, 2022, respectively.

Subsequent events

Subsequent events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent events	Subsequent events The Company has evaluated events subsequent to September 30, 2023 through the date of this filing to assess the need for potential recognition or disclosure. On October 19, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Casdin, whereby the Company sold, and Casdin purchased, 927,165 shares of common stock of the Company, par value $0.001 per share, at a purchase price of $11.19 per share for an aggregate purchase price of $10,374,976.35 (the “Private Placement”). For further information on the Purchase Agreement, please see the Company’s Form 8-K filed with the SEC on October 19, 2023. Additionally, on October 19, 2023, Michael Rice, the Chief Executive Officer and Chairman of the Board of Directors of the Company (the "Board"), retired from his positions as Chairman of the Board and Chief Executive Officer of the Company. Mr. Rice’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Rice’s resignation, the Company and Mr. Rice entered into a Separation, Release of Claims and Consulting Agreement (the "Separation Agreement") on October 19, 2023 (the “Separation Date”), pursuant to which Mr. Rice will serve as a consultant for the Company beginning on the Separation Date and ending on the six-month anniversary thereof. On October 19, 2023, the Board appointed Roderick de Greef as the President and Chief Executive Officer of the Company and Chairman of the Board. In connection with Mr. de Greef’s appointment as Chief Executive Officer, on October 19, 2023, the Company and Mr. de Greef entered into an Employment Agreement (the “de Greef Employment Agreement”). For further information on the resignation of Mr. Rice and appointment of Mr. de Greef, including the Separation Agreement and de Greef Employment Agreement referenced above, please see the Company's Form 8-K filed with the SEC on October 23, 2023. Other than the events outlined above, based upon this evaluation, it was determined that no other subsequent events occurred that require recognition or disclosure in the Consolidated Financial Statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2023 shares	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Aby J. Matthew [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		The following table identifies and provides the material terms of the Rule 10b5-1 trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) adopted or terminated by our officers and directors during the three months ended September 30, 2023. Name and Position Plan Adoption / Termination Plan Adoption / Termination Date Expiration Date Number of Shares Purchased (Sold) / Terminated under Plan Aby J. Mathew, EVP & Chief Scientific Officer (1) Termination August 17, 2023 December 31, 2023 123,404 (1) On August 17, 2023, Aby J. Mathew, EVP & Chief Scientific Officer, terminated the remaining portion of his 10b5-1 Plan originally adopted on November 15, 2022 for the sale of up to 263,404 shares of the Company's common stock until December 31, 2023. The trading arrangement was in place solely for the potential exercise of vested stock options and for sales intended to satisfy tax obligations payable due to the vesting and settlement of certain restricted stock awards. Since the adoption of the 10b5-1 Plan, 140,000 shares of the Company's common stock were sold out of the original 263,404 shares.
Name	Aby J. Mathew
Title	EVP & Chief Scientific Officer
Rule 10b5-1 Arrangement Terminated	true
Termination Date	August 17, 2023
Aggregate Available	263,404	263,404

Organization and significant _2

Organization and significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation	Basis of presentation The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three and nine months ended September 30, 2023 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2023 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023 (the “Annual Report”). The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, Global Cooling, Inc. doing business as Stirling Ultracold (“Global Cooling” or “GCI”), and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Foreign currency translation	Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Comprehensive Loss, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment reporting	Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Concentrations of credit risk and business risk	Concentrations of credit risk and business riskSignificant customers are those that represent more than 10% of the Company’s total revenues or gross accounts receivable balances for the periods and as of each balance sheet date presented.
Recent accounting pronouncements	Recent accounting pronouncements As of January 1, 2023, we adopted the ASC 2016-13, Measurement of Credit Losses on Financial Instruments, which later was codified as ASC 326 (CECL). In addition to the adoption of ASC 326, the Company adopted the accompanying ASU No. 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. Both standards mark a significant change requiring the immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets. ASU 2022-02 specifically eliminates the accounting guidance for troubled debt restructurings and requires disclosure of current-period gross write-offs by year of loan origination. Additionally, ASU 2022-02 updates the accounting for credit losses under ASC 326 and adds enhanced disclosures with respect to loan refinancings and restructurings in the form of principal forgiveness, interest rate concessions, other-than-insignificant payment delays, or term extensions when the borrower is experiencing financial difficulties. ASC 326 is intended to improve financial reporting by corporations by requiring earlier recognition of credit losses on loans from corporations, held-to-maturity (HTM) securities, and certain other financial assets. ASC 326 also amended the impairment guidance for available-for-sale (AFS) debt securities in that it eliminated the Other Than Temporary Impairment (OTTI) impairment model. Under Subtopic ASC 326-30, Financial Instruments—Credit Losses—Available-for-Sale Debt Securities, changes in expected cash flows due to credit on AFS debt securities will be recorded through an allowance, rather than permanent write-downs for negative changes and prospective yield adjustments for positive changes, as required by the current OTTI model. ASC 326 replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. For the period ended September 30, 2023, the adoption of ASC 326 did not result in a material effect on the Company’s Unaudited Condensed Consolidated financial statements.

Organization and significant _3

Organization and significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Concentrations of Credit Risk and Business Risk	For each significant customer, revenue as a percentage of total revenues and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows: Accounts Receivable Revenue September 30, December 31, Three Months Ended Nine Months Ended 2023 2022 2023 2022 2023 2022 Customer A * 15 % * * * * Customer B 11 % * 19 % 17 % 16 % 19 % Customer C * 11 % * * * * * less than 10%
Summary of Product Revenue Concentration	The following table represents the Company’s products representing more than 10% of the Company’s total revenues: Three Months Ended Nine Months Ended Product revenue concentration 2023 2022 2023 2022 CryoStor 33 % 38 % 39 % 35 % 780XLE Freezer 23 % 21 % 19 % 22 %
Summary of Revenue by Geographic Areas	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Nine Months Ended Revenue by customers ’ geographic locations (1) 2023 2022 2023 2022 North America (2) 81 % 81 % 81 % 81 % Europe, Middle East, Africa (EMEA) 15 % 16 % 16 % 16 % Other 4 % 3 % 3 % 3 % Total revenue 100 % 100 % 100 % 100 % (1) During the nine months ended September 30, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.

Correction of immaterial erro_2

Correction of immaterial errors (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
Schedule of Effect of Adjustments to Financial Statements	The effect of the adjustments to our Unaudited Condensed Consolidated Balance Sheet as of September 30, 2022 was as follows: September 30, 2022 (In thousands) As reported Adjustment As corrected Prepaid expenses and other current assets $ 8,041 $ 341 $ 8,382 Total current assets 135,874 341 136,215 Total assets 487,679 341 488,020 Accrued expenses and other current liabilities 7,778 (340) 7,438 Sales taxes payable - 3,810 3,810 Total current liabilities 36,948 3,470 40,418 Total liabilities 79,430 3,470 82,900 Accumulated deficit (194,597) (3,129) (197,726) Total shareholders’ equity 408,249 (3,129) 405,120 Total liabilities and shareholders’ equity 487,679 341 488,020 The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Operations for the quarter ended September 30, 2022 was as follows: Three Months Ended Nine Months Ended (In thousands, except per share and share data) As reported Adjustment As corrected As reported Adjustment As corrected General and administrative $ 11,581 $ 335 $ 11,916 $ 34,128 $ 970 $ 35,098 Total operating expenses 52,152 335 52,487 212,800 970 213,770 Operating loss (11,405) (335) (11,740) (95,300) (970) (96,270) Interest income (expense) 10 (25) (15) (181) (69) (250) Total other income, net 849 (25) 824 786 (69) 717 Loss before income tax benefit (10,556) (360) (10,916) (94,514) (1,039) (95,553) Net loss (9,957) (360) (10,317) (89,577) (1,039) (90,616) Net loss per basic and diluted share (0.23) (0.01) (0.24) (2.11) (0.03) (2.14) The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Cash Flows for the quarter ended September 30, 2022 was as follows: Nine Months Ended (In thousands) As reported Adjustment As corrected Net loss $ (89,577) $ (1,039) $ (90,616) Prepaid expenses and other current assets (1,356) (487) (1,843) Sales taxes payable - 1,526 1,526

Fair value measurement (Tables)

Fair value measurement (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, based on the three-tier fair value hierarchy: (In thousands) As of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 12,392 $ - $ - $ 12,392 Available-for-sale securities: U.S. government securities 5,028 - - 5,028 Corporate debt securities - 15,898 - 15,898 Other debt securities - 2,024 - 2,024 Total $ 17,420 $ 17,922 $ - $ 35,342 Liabilities: Contingent consideration - business combinations - - 415 415 Debt - 25,971 - 25,971 Total $ - $ 25,971 $ 415 $ 26,386 As of December 31, 2022 Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total $ 26,467 $ 29,541 $ - $ 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063
Schedule of the Changes in Fair Value of Contingent Consideration Liabilities	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Nine Months Ended September 30, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 4,456 $ 10,027 Change in fair value recognized in net loss (1,778) (3,348) Payment of contingent consideration earned (2,263) (817) Ending balance $ 415 $ 5,862

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-Sale Marketable Securities	The Company’s portfolio of available-for-sale marketable securities consists of the following: September 30, 2023 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 5,030 $ - $ 2 $ 5,028 Corporate debt securities 15,901 1 4 15,898 Other debt securities 868 - - 868 Total short-term 21,799 1 6 21,794 Available-for-sale securities, long-term Other debt securities 1,158 2 4 1,156 Total marketable securities $ 22,957 $ 3 $ 10 $ 22,950 December 31, 2022 Amortized Gross unrealized Estimated (In thousands) Gains Losses Available-for-sale securities, current portion U.S. government securities $ 15,087 $ 1 $ 37 $ 15,051 Corporate debt securities 26,057 6 16 26,047 Other debt securities 2,169 - 7 2,162 Total short-term 43,313 7 60 43,260 Available-for-sale securities, long-term Other debt securities 1,329 3 - 1,332 Total marketable securities $ 44,642 $ 10 $ 60 $ 44,592 September 30, 2023 (In thousands) Amortized Estimated Due in one year or less $ 21,799 $ 21,794 Due after one year through five years 1,158 1,156 Total $ 22,957 $ 22,950

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Raw materials $ 24,452 $ 20,950 Work in progress 5,973 5,680 Finished goods 12,929 8,274 Total inventories $ 43,354 $ 34,904

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Operating and Finance Lease Terms and Discount Rates	The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Weighted average discount rate - operating leases 4.3 % 4.2 % Weighted average discount rate - finance leases 8.3 % 6.1 % Weighted average remaining lease term in years - operating leases 6.5 7.2 Weighted average remaining lease term in years - finance leases 4.3 2.0
Schedule of Lease Expense	The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Operating lease costs $ 883 $ 909 $ 2,679 $ 2,745 Short-term lease costs 560 534 1,410 1,627 Total operating lease costs 1,443 1,443 4,089 4,372 Variable lease costs 299 250 903 809 Total lease costs $ 1,742 $ 1,693 $ 4,992 $ 5,181
Schedule of Maturities of Operating Lease Liabilities	Maturities of our lease liabilities as of September 30, 2023 are as follows: (In thousands) Operating Financing 2023 (3 months remaining) $ 909 $ 134 2024 3,383 487 2025 2,942 424 2026 2,532 389 2027 2,280 387 Thereafter 6,938 134 Total lease payments 18,984 1,955 Less: interest (2,401) (307) Total present value of lease liabilities $ 16,583 $ 1,648
Schedule of Maturities of Finance Lease Liabilities	Maturities of our lease liabilities as of September 30, 2023 are as follows: (In thousands) Operating Financing 2023 (3 months remaining) $ 909 $ 134 2024 3,383 487 2025 2,942 424 2026 2,532 389 2027 2,280 387 Thereafter 6,938 134 Total lease payments 18,984 1,955 Less: interest (2,401) (307) Total present value of lease liabilities $ 16,583 $ 1,648

Assets held for rent (Tables)

Assets held for rent (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Assets Held For Rent	Assets held for rent consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Shippers placed in service $ 9,848 $ 7,671 Fixed assets held for rent 1,562 4,686 Accumulated depreciation (5,778) (4,952) Subtotal 5,632 7,405 Shippers and related components in production 1,577 1,659 Total $ 7,209 $ 9,064

Property and equipment (Tables)

Property and equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Property and equipment (1) Leasehold improvements $ 5,948 $ 5,249 Furniture and computer equipment 1,046 1,908 Manufacturing and other equipment 19,862 20,557 Construction in-progress 3,500 5,095 Subtotal 30,356 32,809 Less: Accumulated depreciation (9,358) (9,171) Property and equipment, net $ 20,998 $ 23,638 (1) The entirety of the carrying values and accumulated depreciation of the Freezer Business property and equipment assets were impaired during the three months ended September 30, 2023. Refer to Note 3: Impairment of property and equipment and definite-lived intangible assets for more information on the assessed non-cash impairment charges.

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets, net consisted of the following as of September 30, 2023 and December 31, 2022: (In thousands, except weighted average useful life) September 30, 2023 Intangible assets: Gross Carrying Value Accumulated Net Carrying Value Weighted Average Useful Life (in years) Customer relationships (1) $ 9,936 $ (4,081) $ 5,855 10.9 Tradenames (1) 8,134 (1,921) 6,213 11.5 Technology - acquired (1) 18,372 (8,541) 9,831 4.3 Non-compete agreements 750 (585) 165 1.0 Total intangible assets $ 37,192 $ (15,128) $ 22,064 7.6 (1) The entirety of the gross carrying values and accumulated amortization of the specified intangible assets above associated with the Freezer Business were impaired during the three months ended September 30, 2023. Refer to Note 3: Impairment of property and equipment and definite-lived intangible assets for more information on the assessed non-cash impairment charges. (In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value (1) Accumulated Amortization (1) Net Carrying Value Weighted Average Useful Life (in years) (1) Customer relationships $ 10,496 $ (3,328) $ 7,168 8.8 Tradenames 11,328 (1,794) 9,534 11.8 Technology - acquired 23,802 (8,705) 15,097 5.3 Non-compete agreements 750 (461) 289 1.8 Total intangible assets $ 46,376 $ (14,288) $ 32,088 8.0 (1) Both the Gross Carrying Value and Accumulated Amortization balances as of December 31, 2022 contain immaterial adjustments to reflect impairments taken during the year ended December 31, 2022 on each of the intangible asset classes presented here. Each intangible asset class was adjusted as follows: Customer relationships: $0.8 million, Tradenames: $2.4 million, Technology - acquired: $4.1 million, and Non-compete agreements: $0.4 million. The Weighted Average Useful Life was additionally adjusted to reflect the updated balances subsequent to the impairment charges.
Schedule of Amortization Expense for Finite-Lived Intangible Assets	As of September 30, 2023, the Company expects to record the following amortization expense for definite-lived intangible assets: (In thousands) Amortization For the Years Ending December 31, 2023 (3 months remaining) $ 915 2024 3,602 2025 3,468 2026 3,358 2027 2,605 Thereafter 8,116 Total $ 22,064

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) 2023 2022 Accrued compensation $ 3,309 $ 5,080 Accrued expenses 3,704 3,128 Deferred revenue, current 660 548 Accrued taxes 895 975 Other - 51 Total accrued expenses and other current liabilities $ 8,568 $ 9,782

Warranty reserve liability (Tab

Warranty reserve liability (Tables)	9 Months Ended
	Sep. 30, 2023
Guarantees and Product Warranties [Abstract]
Schedule of Product Warranty Liability	A rollforward of our warranty liability is as follows: Nine Months Ended (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 8,312 $ 9,398 Provision for warranties (1) 2,861 2,353 Settlements of warranty claims (1) (2,958) (3,384) Ending balance $ 8,215 $ 8,367

Long-term debt (Tables)

Long-term debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt consisted of the following as of September 30, 2023 and December 31, 2022: September 30, December 31, (In thousands) Maturity Date Interest Rate 2023 2022 2022 term loan 2 Various 4.0 % 2,596 2,896 2022 term loan 3 Jun-26 7.0 % 20,000 20,000 Insurance premium financing Apr-24 8.0 % 2,061 1,074 Freezer equipment loan Dec-25 5.7 % 355 466 Manufacturing equipment loans Oct-25 5.7 % 195 266 Freezer installation loan Various 6.3 % 876 1,078 Other loans Various Various 3 6 Total debt, excluding unamortized debt issuance costs 26,086 25,786 Less: unamortized debt issuance costs (115) (179) Total debt 25,971 25,607 Less: current portion (5,034) (1,814) Total long-term debt $ 20,937 $ 23,793
Schedule of Maturities of Long-Term Debt	As of September 30, 2023, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows: (In thousands) Amount 2023 (3 months remaining) $ 816 2024 6,830 2025 10,511 2026 5,218 2027 2,596 Thereafter - Total debt $ 25,971

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Bioproduction Tools and Service Revenues	Total bioproduction tools and services revenue for the three and nine months ended September 30, 2023 and 2022 were composed of the following: Three Months Ended Nine Months Ended (In thousands, except percentages) 2023 2022 2023 2022 Product revenue Freezer and thaw $ 13,188 $ 15,326 $ 39,417 $ 49,331 Cell processing 13,338 18,082 51,004 48,336 Biostorage services 365 260 1,099 560 Service revenue Biostorage services 4,186 4,312 12,166 11,099 Freezer and thaw 192 18 877 18 Rental revenue Biostorage services 2,059 2,749 5,975 8,156 Total revenue $ 33,328 $ 40,747 $ 110,538 $ 117,500
Schedule of Remaining Performance Obligations	The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: (In thousands) 2023 (3 months remaining) 2024 Total Rental revenue $ 900 $ 900 $ 1,800 Service revenue $ 313 $ 10 $ 323

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Service Vesting-Based Stock Option Activity	The following is a summary of service vesting-based stock option activity for the September 30, 2023, and the status of service vesting-based stock options outstanding as of September 30, 2023: Nine Months Ended Options Wtd. Avg. Exercise Price Outstanding as of beginning of year 456,293 $ 2.17 Exercised (175,043) 2.11 Outstanding as of September 30, 2023 281,250 $ 2.19 Stock options exercisable as of September 30, 2023 281,250 $ 2.19
Summary of Service Vesting-Based and Market Based Restricted Stock Activity	The following is a summary of service vesting-based restricted stock activity for the three and nine months ended September 30, 2023, and the status of unvested service vesting-based restricted stock outstanding as of September 30, 2023: Nine Months Ended Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,879,215 $ 28.94 Granted 584,976 17.57 Vested (892,512) 25.95 Forfeited (151,984) 28.25 Non-vested as of September 30, 2023 1,419,695 $ 26.21 The following is a summary of market-based restricted stock activity under our stock option plan for the three and nine months ended September 30, 2023 and the status of market-based restricted stock outstanding as of September 30, 2023: Nine Months Ended Shares Wtd. Avg. Grant Outstanding as of beginning of year 271,044 $ 30.64 Granted 268,738 19.67 Vested (30,616) 51.65 Non-vested as of September 30, 2023 509,166 $ 26.00
Summary of Stock Compensation Expense	We recorded total stock compensation expense for the three and nine months ended September 30, 2023 and 2022, as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Cost of revenue $ 1,409 $ 809 $ 4,252 $ 2,619 General and administrative costs 3,696 3,959 10,544 10,687 Sales and marketing costs 2,225 829 4,563 2,272 Research and development costs 1,787 702 3,978 2,093 Total $ 9,117 $ 6,299 $ 23,337 $ 17,671

Net loss per common share (Tabl

Net loss per common share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted, Two Class Method	The following table presents computations of basic and diluted earnings per share: Three Months Ended Nine Months Ended (In thousands, except share and earnings per share data) 2023 2022 2023 2022 Basic earnings (loss) per common share Numerator: Net loss $ (29,132) $ (10,317) $ (53,045) $ (90,616) Net loss allocated to common shareholders (29,132) (10,317) (53,045) (90,616) Denominator: Weighted-average common shares issued and outstanding 43,570,438 42,647,967 43,348,412 42,376,392 Basic and diluted loss per common share $ (0.67) $ (0.24) $ (1.22) $ (2.14)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Stock options and restricted stock awards 2,636,283 2,022,405 3,007,126 2,678,601 Total 2,636,283 2,022,405 3,007,126 2,678,601

Organization and significant _4

Organization and significant accounting policies - Narrative (Details)		3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 19, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($) reporting_unit reportable_segment	Dec. 31, 2022 USD ($)	Sep. 20, 2022 USD ($)
Short-Term Debt [Line Items]
Number of reportable segments | reportable_segment			1
Number of reporting units | reporting_unit			1
Cash, cash equivalents, and available-for-sale securities		$ 42,200,000	$ 42,200,000	$ 64,100,000
Subsequent Event | Casdin Securities Purchase Agreement
Short-Term Debt [Line Items]
Number of shares sold (in shares) | shares	927,165
Shares sold, price per share (in dollars per share) | $ / shares	$ 11.19
Consideration received on sale of stock	$ 10,374,976.35
Supplier Concentration Risk | Supply Purchase | One Supplier
Short-Term Debt [Line Items]
Concentration risk, percent		14%	12%
Supplier Concentration Risk | Accounts Payable | One Supplier
Short-Term Debt [Line Items]
Concentration risk, percent			19%	23%
2022 term loan 3
Short-Term Debt [Line Items]
Maximum borrowing capacity		$ 10,000,000	$ 10,000,000		$ 30,000,000

Organization and significant _5

Organization and significant accounting policies - Schedule of Concentrations of Credit Risk and Business Risk (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percent					15%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percent			11%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percent					11%
Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percent	19%	17%	16%	19%

Organization and significant _6

Organization and significant accounting policies - Summary of Product Revenue Concentration (Details) - Revenue	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product revenue concentration | CryoStor
Concentration Risk [Line Items]
Concentration risk, percent	33%	38%	39%	35%
Product revenue concentration | 780XLE Freezer
Concentration Risk [Line Items]
Concentration risk, percent	23%	21%	19%	22%
Revenue by customers' geographic locations
Concentration Risk [Line Items]
Concentration risk, percent	100%	100%	100%	100%
Revenue by customers' geographic locations | North America
Concentration Risk [Line Items]
Concentration risk, percent	81%	81%	81%	81%
Revenue by customers' geographic locations | Europe, Middle East, Africa (EMEA)
Concentration Risk [Line Items]
Concentration risk, percent	15%	16%	16%	16%
Revenue by customers' geographic locations | Other
Concentration Risk [Line Items]
Concentration risk, percent	4%	3%	3%	3%

Correction of immaterial erro_3

Correction of immaterial errors - Schedule of Effect of Adjustments to Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Unaudited Condensed Consolidated Balance Sheet
Prepaid expenses and other current assets	$ 7,854	$ 8,382	$ 7,854	$ 8,382		$ 6,879
Total current assets	116,824	136,215	116,824	136,215		138,452
Total assets	411,152	488,020	411,152	488,020		450,229
Accrued expenses and other current liabilities	8,568	7,438	8,568	7,438		9,782
Sales taxes payable	5,469	3,810	5,469	3,810		4,151
Total current liabilities	42,622	40,418	42,622	40,418		44,582
Total liabilities	79,135	82,900	79,135	82,900		86,041
Accumulated deficit	(299,960)	(197,726)	(299,960)	(197,726)		(246,915)
Total shareholders’ equity	332,017	405,120	332,017	405,120	$ 352,128	364,188	$ 409,544	$ 478,047
Total liabilities and shareholders’ equity	411,152	488,020	411,152	488,020		$ 450,229
Unaudited Condensed Consolidated Statements of Operations
General and administrative	12,513	11,916	42,757	35,098
Total operating expenses	62,111	52,487	168,208	213,770
Operating loss	(28,783)	(11,740)	(57,670)	(96,270)
Interest income (expense)	(476)	(15)	(1,305)	(250)
Total other income, net	(234)	824	4,837	717
Loss before income tax benefit	(29,017)	(10,916)	(52,833)	(95,553)
Net loss	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Net loss per share attributable to common shareholders, basic (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)
Net loss per share attributable to common shareholders, diluted (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)
Unaudited Condensed Consolidated Statement of Cash Flows
Net loss	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Prepaid expenses and other current assets			(1,045)	(1,843)
Sales taxes payable			$ 1,330	1,526
As reported
Unaudited Condensed Consolidated Balance Sheet
Prepaid expenses and other current assets		8,041		8,041
Total current assets		135,874		135,874
Total assets		487,679		487,679
Accrued expenses and other current liabilities		7,778		7,778
Sales taxes payable		0		0
Total current liabilities		36,948		36,948
Total liabilities		79,430		79,430
Accumulated deficit		(194,597)		(194,597)
Total shareholders’ equity		408,249		408,249
Total liabilities and shareholders’ equity		487,679		487,679
Unaudited Condensed Consolidated Statements of Operations
General and administrative		11,581		34,128
Total operating expenses		52,152		212,800
Operating loss		(11,405)		(95,300)
Interest income (expense)		10		(181)
Total other income, net		849		786
Loss before income tax benefit		(10,556)		(94,514)
Net loss		$ (9,957)		$ (89,577)
Net loss per share attributable to common shareholders, basic (in dollars per share)		$ (0.23)		$ (2.11)
Net loss per share attributable to common shareholders, diluted (in dollars per share)		$ (0.23)		$ (2.11)
Unaudited Condensed Consolidated Statement of Cash Flows
Net loss		$ (9,957)		$ (89,577)
Prepaid expenses and other current assets				(1,356)
Sales taxes payable				0
Adjustment
Unaudited Condensed Consolidated Balance Sheet
Prepaid expenses and other current assets		341		341
Total current assets		341		341
Total assets		341		341
Accrued expenses and other current liabilities		(340)		(340)
Sales taxes payable		3,810		3,810
Total current liabilities		3,470		3,470
Total liabilities		3,470		3,470
Accumulated deficit		(3,129)		(3,129)
Total shareholders’ equity		(3,129)		(3,129)
Total liabilities and shareholders’ equity		341		341
Unaudited Condensed Consolidated Statements of Operations
General and administrative		335		970
Total operating expenses		335		970
Operating loss		(335)		(970)
Interest income (expense)		(25)		(69)
Total other income, net		(25)		(69)
Loss before income tax benefit		(360)		(1,039)
Net loss		$ (360)		$ (1,039)
Net loss per share attributable to common shareholders, basic (in dollars per share)		$ (0.01)		$ (0.03)
Net loss per share attributable to common shareholders, diluted (in dollars per share)		$ (0.01)		$ (0.03)
Unaudited Condensed Consolidated Statement of Cash Flows
Net loss		$ (360)		$ (1,039)
Prepaid expenses and other current assets				(487)
Sales taxes payable				$ 1,526

Impairment of property and eq_2

Impairment of property and equipment and definite-lived intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets		$ 9,727	$ 0
Freezer Business
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets	$ 9,700
Impairment of intangible assets, finite-lived	5,800
Technology - acquired
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				$ 4,100
Technology - acquired | Freezer Business
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	3,100
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				800
Customer relationships | Freezer Business
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	200
Tradenames
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived				$ 2,400
Tradenames | Freezer Business
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived	$ 2,500

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2023 USD ($)	Jun. 30, 2023 shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Oct. 01, 2020 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Change in fair value of contingent consideration, increase (decrease)	$ (1,580)		$ 2,346	$ (1,778)	$ (3,348)
Shares Issued As Payment for Contingent Consideration Liability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Shares issued as payment (in shares) | shares		116,973
SciSafe Holdings, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, liability	300			300		$ 4,300	$ 3,700
Change in fair value of contingent consideration, increase (decrease)	$ (1,600)		$ 2,300	$ (1,800)	$ (3,300)
SciSafe Holdings, Inc | Discount Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, liability, measurement input	0.145			0.145			0.045
SciSafe Holdings, Inc | Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, liability, measurement input	0.049			0.049			0.0020
SciSafe Holdings, Inc | Asset Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, liability, measurement input	0.71			0.71			0.60
SciSafe Holdings, Inc | Revenue Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, liability, measurement input	0.36			0.36			0.15

Fair value measurement - Schedu

Fair value measurement - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$ 22,950	$ 44,592
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	35,342	56,008
Contingent consideration - business combinations	415	4,456
Debt	25,971	25,607
Liabilities	26,386	30,063
Fair Value, Recurring | U.S. government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	5,028	15,051
Fair Value, Recurring | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	15,898	26,047
Fair Value, Recurring | Other debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	2,024	3,494
Fair Value, Recurring | Money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	12,392	11,416
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	17,420	26,467
Contingent consideration - business combinations	0	0
Debt	0	0
Liabilities	0	0
Fair Value, Recurring | Level 1 | U.S. government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	5,028	15,051
Fair Value, Recurring | Level 1 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 1 | Other debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 1 | Money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	12,392	11,416
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	17,922	29,541
Contingent consideration - business combinations	0	0
Debt	25,971	25,607
Liabilities	25,971	25,607
Fair Value, Recurring | Level 2 | U.S. government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 2 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	15,898	26,047
Fair Value, Recurring | Level 2 | Other debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	2,024	3,494
Fair Value, Recurring | Level 2 | Money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0
Contingent consideration - business combinations	415	4,456
Debt	0	0
Liabilities	415	4,456
Fair Value, Recurring | Level 3 | U.S. government securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 3 | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 3 | Other debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Fair Value, Recurring | Level 3 | Money market accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0	$ 0

Fair value measurement - Sche_2

Fair value measurement - Schedule of the Changes in Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 4,456	$ 10,027
Change in fair value recognized in net loss	(1,778)	(3,348)
Payment of contingent consideration earned	(2,263)	(817)
Ending balance	$ 415	$ 5,862

Investments - Schedule of Avail

Investments - Schedule of Available-for-Sale Marketable Securities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, Current	$ 21,799	$ 43,313
Gross Unrealized Gains, Current	1	7
Gross Unrealized Losses, Current	6	60
Available-for-sale securities, current portion	21,794	43,260
Amortized Cost, Noncurrent	1,158
Available-for-sale securities, long-term	1,156	1,332
Total marketable securities, Amortized Cost	22,957	44,642
Total marketable securities, Gross Unrealized Gains	3	10
Total marketable securities, Gross Unrealized Losses	10	60
Total marketable securities, Estimated Fair Value	22,950	44,592
Due in one year or less, Amortized Cost	21,799	43,313
Due in one year or less, Estimated Fair Value	21,794	43,260
Due after one year through five years, Amortized Cost	1,158
Due after one year through five years, Estimated Fair Value	1,156
Total, Amortized Cost	22,957	44,642
U.S. government securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, Current	5,030	15,087
Gross Unrealized Gains, Current	0	1
Gross Unrealized Losses, Current	2	37
Available-for-sale securities, current portion	5,028	15,051
Due in one year or less, Amortized Cost	5,030	15,087
Due in one year or less, Estimated Fair Value	5,028	15,051
Corporate debt securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, Current	15,901	26,057
Gross Unrealized Gains, Current	1	6
Gross Unrealized Losses, Current	4	16
Available-for-sale securities, current portion	15,898	26,047
Due in one year or less, Amortized Cost	15,901	26,057
Due in one year or less, Estimated Fair Value	15,898	26,047
Other debt securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost, Current	868	2,169
Gross Unrealized Gains, Current	0	0
Gross Unrealized Losses, Current	0	7
Available-for-sale securities, current portion	868	2,162
Amortized Cost, Noncurrent	1,158	1,329
Gross Unrealized Gains, Noncurrent	2	3
Gross Unrealized Losses, Noncurrent	4	0
Available-for-sale securities, long-term	1,156	1,332
Due in one year or less, Amortized Cost	868	2,169
Due in one year or less, Estimated Fair Value	868	2,162
Due after one year through five years, Amortized Cost	$ 1,158	$ 1,329

Investments - Narrative (Detail

Investments - Narrative (Details) - Contingent Convertible Preferred Stock - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Series A-1 and A-2, Preferred Stock
Debt and Equity Securities, FV-NI [Line Items]
Fair value of non-marketable equity securities without readily determinable fair value	$ 4,100	$ 4,100
Series E Preferred Stock
Debt and Equity Securities, FV-NI [Line Items]
Fair value of non-marketable equity securities without readily determinable fair value	$ 995	$ 995

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 24,452	$ 20,950
Work in progress	5,973	5,680
Finished goods	12,929	8,274
Total inventories	$ 43,354	$ 34,904

Leases - Narrative (Details)

Leases - Narrative (Details)	Sep. 30, 2023
Real Estate Lease | Minimum
Lessee, Lease, Description [Line Items]
Operating lease, remaining lease term	1 year
Operating lease, renewal term	1 year
Real Estate Lease | Maximum
Lessee, Lease, Description [Line Items]
Operating lease, remaining lease term	10 years
Operating lease, renewal term	5 years
Vehicle and Other Equipment | Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	1 year
Vehicle and Other Equipment | Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	5 years

Leases - Schedule of Operating

Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted average discount rate - operating leases	4.30%	4.20%
Weighted average discount rate - finance leases	8.30%	6.10%
Weighted average remaining lease term in years - operating leases	6 years 6 months	7 years 2 months 12 days
Weighted average remaining lease term in years - finance leases	4 years 3 months 18 days	2 years

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease costs	$ 883	$ 909	$ 2,679	$ 2,745
Short-term lease costs	560	534	1,410	1,627
Total operating lease costs	1,443	1,443	4,089	4,372
Variable lease costs	299	250	903	809
Total lease costs	$ 1,742	$ 1,693	$ 4,992	$ 5,181

Leases - Maturities of Operatin

Leases - Maturities of Operating and Finance Lease Liabilities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Leases
2023 (3 months remaining)	$ 909
2024	3,383
2025	2,942
2026	2,532
2027	2,280
Thereafter	6,938
Total lease payments	18,984
Less: interest	(2,401)
Total present value of lease liabilities	16,583
Financing Leases
2023 (3 months remaining)	134
2024	487
2025	424
2026	389
2027	387
Thereafter	134
Total lease payments	1,955
Less: interest	(307)
Total present value of lease liabilities	$ 1,648

Assets held for rent - Summary

Assets held for rent - Summary of Assets Held for Rent (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Shippers placed in service	$ 9,848	$ 7,671
Fixed assets held for rent	1,562	4,686
Accumulated depreciation	(5,778)	(4,952)
Subtotal	5,632	7,405
Shippers and related components in production	1,577	1,659
Total	$ 7,209	$ 9,064

Assets held for rent - Narrativ

Assets held for rent - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Assets held for rent, depreciation expense	$ 0.9	$ 0.9	$ 2.8	$ 2.7

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Subtotal	$ 30,356	$ 32,809
Less: Accumulated depreciation	(9,358)	(9,171)
Property and equipment, net	20,998	23,638
Leasehold improvements
Property, Plant and Equipment [Line Items]
Subtotal	5,948	5,249
Furniture and computer equipment
Property, Plant and Equipment [Line Items]
Subtotal	1,046	1,908
Manufacturing and other equipment
Property, Plant and Equipment [Line Items]
Subtotal	19,862	20,557
Construction in-progress
Property, Plant and Equipment [Line Items]
Subtotal	$ 3,500	$ 5,095

Property and equipment - Narrat

Property and equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, depreciation expense	$ 1	$ 0.9	$ 2.9	$ 2.4

Goodwill and intangible asset_2

Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (14,288)	$ (15,128)
Total		$ 22,064
Weighted Average Useful Life (in years)	8 years	7 years 7 months 6 days
Intangible assets, gross	$ 46,376	$ 37,192
Intangible assets, net	32,088	22,064
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	10,496	9,936
Accumulated Amortization	(3,328)	(4,081)
Total	$ 7,168	$ 5,855
Weighted Average Useful Life (in years)	8 years 9 months 18 days	10 years 10 months 24 days
Impairment of intangible assets, finite-lived	$ 800
Tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	11,328	$ 8,134
Accumulated Amortization	(1,794)	(1,921)
Total	$ 9,534	$ 6,213
Weighted Average Useful Life (in years)	11 years 9 months 18 days	11 years 6 months
Impairment of intangible assets, finite-lived	$ 2,400
Technology - acquired
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	23,802	$ 18,372
Accumulated Amortization	(8,705)	(8,541)
Total	$ 15,097	$ 9,831
Weighted Average Useful Life (in years)	5 years 3 months 18 days	4 years 3 months 18 days
Impairment of intangible assets, finite-lived	$ 4,100
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	750	$ 750
Accumulated Amortization	(461)	(585)
Total	$ 289	$ 165
Weighted Average Useful Life (in years)	1 year 9 months 18 days	1 year
Impairment of intangible assets, finite-lived	$ 400

Goodwill and intangible asset_3

Goodwill and intangible assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible asset amortization	$ 1,356	$ 2,513	$ 4,266	$ 8,236

Goodwill and intangible asset_4

Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (3 months remaining)	$ 915
2024	3,602
2025	3,468
2026	3,358
2027	2,605
Thereafter	8,116
Total	$ 22,064

Accrued expenses and other cu_3

Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Accrued compensation	$ 3,309	$ 5,080
Accrued expenses	3,704	3,128
Deferred revenue, current	660	548
Accrued taxes	895	975
Other	0	51
Total accrued expenses and other current liabilities	$ 8,568	$ 9,782	$ 7,438

Warranty reserve liability - Sc

Warranty reserve liability - Schedule of Product Warranty Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning balance as of December 31, 2022 and 2021	$ 8,312	$ 9,398
Provision for warranties	2,861	2,353
Settlements of warranty claims	(2,958)	(3,384)
Ending balance	$ 8,215	8,367
Immaterial reclassifications		$ 600

Commitments and contingencies (

Commitments and contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 05, 2023	Dec. 31, 2022	May 03, 2021
Other Commitments [Line Items]
Short-term purchase obligations	$ 14,300		$ 14,300
Sales and excise tax payable	5,200		5,200			$ 3,700
Sales taxes assessed	$ 100		$ 100			$ 300
Common stock, shares issued (in shares)	43,831,351		43,831,351			42,832,231
Common stock, shares outstanding (in shares)	43,831,351		43,831,351			42,832,231
Gain on settlement of Global Cooling escrow	$ 0	$ 0	$ 5,115	$ 0
GCI Escrow
Other Commitments [Line Items]
Common stock, shares issued (in shares)							6,646,870
GCI Escrow | General Escrow Shares
Other Commitments [Line Items]
Shares deposited into escrow, percent							5%
GCI Escrow | General Escrow Shares | Settled Litigation
Other Commitments [Line Items]
Shares deposited into escrow, percent					65%
Common stock, shares outstanding (in shares)					216,024
GCI Escrow | Escrow Shares
Other Commitments [Line Items]
Shares deposited into escrow, percent							9%
Shares deposited into escrow, holding term							18 months

Long-term debt - Narrative (Det

Long-term debt - Narrative (Details) $ in Thousands	Sep. 20, 2022 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 supplier note	Oct. 31, 2021 USD ($) note
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs		$ 26,086	$ 25,786
Debt instrument, balloon payment due	$ 1,200
2022 term loan 2
Debt Instrument [Line Items]
Number of term loans | note				3	3
Number of term loans extinguished | supplier				1
Total debt, excluding unamortized debt issuance costs		$ 2,596	2,896
Interest Rate		4%			4%
Term Note 1
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs					$ 1,400
Term Note 2
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs					1,400
Term Note 3
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs					$ 1,800
2022 term loan 3
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs		$ 20,000	$ 20,000
Interest Rate		7%
Debt instrument, maximum borrowing capacity	50,000
Maximum borrowing capacity	30,000	$ 10,000
Debt instrument, additional maximum amount within nine months after closing	10,000
Debt instrument, additional maximum amount upon certain milestone achievements	10,000
Debt instrument, additional maximum at discretion of lender	10,000
Debt instrument, face amount	$ 20,000	$ 20,000
Debt instrument, interest rate, maximum stated percentage for each tranche borrowed	1%
2022 term loan 3 | Prime Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%

Long-term debt - Schedule of De

Long-term debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Oct. 31, 2021
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs	$ 26,086	$ 25,786
Less: unamortized debt issuance costs	(115)	(179)
Total debt	25,971	25,607
Less: current portion	(5,034)	(1,814)
Total long-term debt	$ 20,937	23,793
2022 term loan 2
Debt Instrument [Line Items]
Interest Rate	4%		4%
Total debt, excluding unamortized debt issuance costs	$ 2,596	2,896
2022 term loan 3
Debt Instrument [Line Items]
Interest Rate	7%
Total debt, excluding unamortized debt issuance costs	$ 20,000	20,000
Insurance premium financing
Debt Instrument [Line Items]
Interest Rate	8%
Total debt, excluding unamortized debt issuance costs	$ 2,061	1,074
Freezer equipment loan
Debt Instrument [Line Items]
Interest Rate	5.70%
Total debt, excluding unamortized debt issuance costs	$ 355	466
Manufacturing equipment loans
Debt Instrument [Line Items]
Interest Rate	5.70%
Total debt, excluding unamortized debt issuance costs	$ 195	266
Freezer installation loan
Debt Instrument [Line Items]
Interest Rate	6.30%
Total debt, excluding unamortized debt issuance costs	$ 876	1,078
Other loans
Debt Instrument [Line Items]
Total debt, excluding unamortized debt issuance costs	3	6
Total long-term debt
Debt Instrument [Line Items]
Total long-term debt	$ 20,937	$ 23,793

Long-term debt - Schedule of Ma

Long-term debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023 (3 months remaining)	$ 816
2024	6,830
2025	10,511
2026	5,218
2027	2,596
Thereafter	0
Total debt	$ 25,971	$ 25,607

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Deferred revenue	$ 700		$ 700		$ 600
Deferred revenue, revenue recognized	$ 100	$ 26	$ 400	$ 500

Revenue - Summary of Bioproduct

Revenue - Summary of Bioproduction Tools and Service Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	$ 33,328	$ 40,747	$ 110,538	$ 117,500
Product revenue
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	26,891	33,668	91,520	98,227
Freezer and thaw
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	13,188	15,326	39,417	49,331
Cell processing
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	13,338	18,082	51,004	48,336
Biostorage services
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	365	260	1,099	560
Service revenue
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	4,378	4,330	13,043	11,117
Biostorage services
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	4,186	4,312	12,166	11,099
Freezer and thaw
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	192	18	877	18
Rental revenue
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	2,059	2,749	5,975	8,156
Biostorage services
Disaggregation of Revenue [Line Items]
Total product, rental, and service revenue	$ 2,059	$ 2,749	$ 5,975	$ 8,156

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Rental revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1,800
Service revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	323
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Rental revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 900
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 | Service revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 313
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Rental revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 900
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Service revenue
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 10
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Stock-based compensation - Summ

Stock-based compensation - Summary of Service Vesting-Based Stock Option Activity (Details) - Options - $ / shares	9 Months Ended
	Sep. 30, 2023
Options
Outstanding as of beginning of period (in shares)	456,293
Exercised (in shares)	(175,043)
Outstanding as of end of period (in shares)	281,250
Stock options exercisable at end of period (in shares)	281,250
Wtd. Avg. Exercise Price
Outstanding as of beginning of period (in dollars per share)	$ 2.17
Exercised (in dollars per share)	2.11
Outstanding as of end of period (in dollars per share)	2.19
Stock options exercisable at end of period (in dollars per share)	$ 2.19

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details)					3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023 shares	Jan. 08, 2023 USD ($) peer shares	Feb. 24, 2022 USD ($) peer shares	Feb. 08, 2021 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 peer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, expense					$ 9,117,000	$ 6,299,000	$ 23,337,000	$ 17,671,000
Number of peers | peer		20	20						20
Share-based compensation arrangement by share-based payment award, vesting period							4 years
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value					3,300,000		$ 3,300,000
Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value					$ 500,000		$ 3,300,000
Share-based compensation arrangement by share-based payment award, options, grants in period, gross (in shares) | shares					0		0
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term							2 years 3 months 18 days
Share-based payment arrangement, nonvested award, cost not yet recognized, amount					$ 0		$ 0
Restricted Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount					33,000,000		33,000,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, fair value					1,000,000		16,800,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value					5,000,000		16,900,000
Share-based payment arrangement, expense					9,100,000		$ 23,300,000
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition							2 years 2 months 12 days
Granted (in shares) | shares							584,976
Market-based Restricted Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount					4,900,000		$ 4,900,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, fair value				$ 1,300,000
Share-based payment arrangement, expense					$ 1,600,000	1,200,000	$ 4,900,000	3,100,000
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition							1 year 1 month 6 days
Granted (in shares) | shares					268,738
Share-based compensation arrangement by share-based payment award, percentage of awards	100%
Share-based compensation arrangement by share-based payment award, fair value assumptions, historical volatility rate		78%	63%	68%
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate		0%	0%	0%
Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate		4.40%	1.50%	0.10%
Share-based compensation arrangement by Share-based payment award, fair value assumptions, expected volatility rate period		2 years	2 years	2 years
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, aggregate fair value					$ 0	$ 0	$ 6,500,000	6,700,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested							$ 700,000	$ 5,000,000
Market-based Restricted Stock | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, percentage of awards		0%	0%
Market-based Restricted Stock | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, percentage of awards		200%	200%
Market-based Restricted Stock | Executive Officer
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment arrangement, expense		$ 6,800,000	$ 6,700,000
Granted (in shares) | shares	30,616	268,738	240,428	30,616

Stock-based compensation - Su_2

Stock-based compensation - Summary of Service Vesting-Based and Market Based Restricted Stock Activity (Details) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Restricted Stock
Shares
Outstanding as of beginning of period (in shares)		1,879,215
Granted (in shares)		584,976
Vested (in shares)		(892,512)
Forfeited (in shares)		(151,984)
Outstanding as of end of period (in shares)	1,419,695	1,419,695
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period (in dollars per share)		$ 28.94
Granted (in dollars per share)		17.57
Vested (in dollars per share)		25.95
Forfeited (in dollars per share)		28.25
Outstanding as of end of period (in dollars per share)	$ 26.21	$ 26.21
Market-based Restricted Stock
Shares
Outstanding as of beginning of period (in shares)		271,044
Granted (in shares)	268,738
Vested (in shares)	(30,616)
Outstanding as of end of period (in shares)	509,166	509,166
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period (in dollars per share)		$ 30.64
Granted (in dollars per share)	$ 19.67
Vested (in dollars per share)	51.65
Outstanding as of end of period (in dollars per share)	$ 26	$ 26

Stock-based compensation - Su_3

Stock-based compensation - Summary of Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 9,117	$ 6,299	$ 23,337	$ 17,671
Cost of revenue
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	1,409	809	4,252	2,619
General and administrative costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	3,696	3,959	10,544	10,687
Sales and marketing costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	2,225	829	4,563	2,272
Research and development costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 1,787	$ 702	$ 3,978	$ 2,093

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 115	$ (599)	$ 212	$ (4,937)
Effective income tax rate reconciliation, percent			(0.40%)
Effective income tax rate reconciliation, tax benefit, share-based payment arrangement, amount			$ 1,200
Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent			(0.40%)
Effective income tax rate reconciliation, at federal statutory income tax rate, percent			21%
Deferred tax assets, valuation allowance	$ 48,200		$ 48,200

Net loss per common share - Sch

Net loss per common share - Schedule of Earnings Per Share, Basic and Diluted, Two Class Method (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Net loss allocated to common shareholders	(29,132)	(10,317)	(53,045)	(90,616)
Net loss allocated to common shareholders	$ (29,132)	$ (10,317)	$ (53,045)	$ (90,616)
Denominator:
Weighted average common shares issued, basic (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Weighted average common shares outstanding, basic (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Weighted average common shares issued, diluted (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Weighted average common shares outstanding, diluted (in shares)	43,570,438	42,647,967	43,348,412	42,376,392
Net loss per share attributable to common shareholders, basic (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)
Net loss per share attributable to common shareholders, diluted (in dollars per share)	$ (0.67)	$ (0.24)	$ (1.22)	$ (2.14)

Net loss per common share - S_2

Net loss per common share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,636,283	2,022,405	3,007,126	2,678,601
Stock options and restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,636,283	2,022,405	3,007,126	2,678,601

Employee benefit plan - Narrati

Employee benefit plan - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Retirement Benefits [Abstract]
Defined contribution plan, employer matching contribution, percent of employees' gross pay	100%
Defined contribution plan, employer discretionary contribution amount	$ 0.3	$ 0.3	$ 0.9	$ 0.8

Subsequent events (Details)

Subsequent events (Details) - USD ($)	Oct. 19, 2023	Sep. 30, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Subsequent Event | Casdin Securities Purchase Agreement
Subsequent Event [Line Items]
Number of shares sold (in shares)	927,165
Common stock, par value (in dollars per share)	$ 0.001
Shares sold, price per share (in dollars per share)	$ 11.19
Consideration received on sale of stock	$ 10,374,976.35